Oppenheimer Reiterates Outperform on Zentalis Pharma, Maintains $50 Price Target
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Matthew Biegler has reiterated an Outperform rating on Zentalis Pharma (NASDAQ:ZNTL) and maintained a $50 price target.
May 26, 2023 | 3:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer analyst Matthew Biegler reiterated an Outperform rating on Zentalis Pharma and maintained a $50 price target.
The reiteration of the Outperform rating and maintenance of the $50 price target by Oppenheimer analyst Matthew Biegler indicates a positive outlook for Zentalis Pharma. This news is likely to have a positive impact on the stock price in the short term as it reaffirms the confidence of a well-respected analyst in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100